Nicholas Investment Partners, LP Viking Therapeutics, Inc. Transaction History

Nicholas Investment Partners, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$17.4 - $94.5 $1.39 Million - $7.56 Million	80,010 New	80,010 $6.56 Million
Q2 2023 Aug 09, 2023	SELL	$14.84 - $24.79 $6.5 Million - $10.9 Million	-438,165 Reduced 86.41%	68,905 $1.12 Million
Q1 2023 May 11, 2023	BUY	$8.08 - $17.33 $4.1 Million - $8.79 Million	507,070 New	507,070 $8.44 Million
Q3 2019 Nov 13, 2019	SELL	$6.55 - $8.6 $3.17 Million - $4.16 Million	-483,951 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$7.67 - $10.63 $82,674 - $114,580	-10,779 Reduced 2.18%	483,951 $4.02 Million
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $24,498 - $32,126	-3,232 Reduced 0.65%	494,730 $4.92 Million
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $587,592 - $1.33 Million	-82,066 Reduced 14.15%	497,962 $3.81 Million
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $613,398 - $1.24 Million	63,237 Added 12.24%	580,028 $10.1 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $2.01 Million - $6.58 Million	516,791 New	516,791 $4.9 Million

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.